PPD acquires healthcare research biz Evidera


Global CRO PPD joined forces with research-based consulting company Evidera. The Bethesda, MD-based company helps pharmas and biotechs demonstrate value in the research stages.

The companies didn’t reveal the monetary terms of the agreement, but Evidera will become a wholly owned subsidiary of the CRO giant. The addition of the firm should give PPD access to capabilities and expertise that promises a leg up in the pharma and biotech space.

“Our acquisition of Evidera demonstrates PPD’s commitment to strategic investments that enable our clients to advance the generation of real-world evidence to more efficiently deliver life-changing therapies that improve health,” PPD CEO David Simmons said. “We are dedicated to providing our clients a superior integration of scientific knowledge, technology and high-quality delivery to maximize the productivity of their R&D investments and to accelerate patient access to life-changing therapies.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Evidera will continue to operate its offices in North America and Europe and serve many of the top biopharma companies. The deal should close within the next few months, according to a release.

- here's the release


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.